Human mesenchymal stem cells attenuate hyperoxia-induced lung injury through inhibition of the renin-angiotensin system in newborn rats.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed, 24 citations in OpenAlex.

1. Can mesenchymal stem cell and retinoic acid therapies more effectively reduce lung damage due to bronchopulmonary dysplasia?Italian journal of pediatrics · 2026
   Article
2. Intratracheal administration of umbilical cord-derived mesenchymal stem cells attenuates hyperoxia-induced multi-organ injuryWorld journal of stem cells · 2022
   Article
3. Stem-Cell Therapy for Bronchopulmonary Dysplasia (BPD) in Newborns.Cells · 2022
   Review
4. Hyperoxia Induces Ferroptosis and Impairs Lung Development in Neonatal Mice.Antioxidants (Basel, Switzerland) · 2022
   Article
5. Consecutive daily administration of intratracheal surfactant and human umbilical cord-derived mesenchymal stem cells attenuates hyperoxia-induced lung injury in neonatal rats.Stem cell research & therapy · 2021
   Article
6. Effects of Mesenchymal Stromal Cell-Derived Extracellular Vesicles in Lung Diseases: Current Status and Future Perspectives.Stem cell reviews and reports · 2021
   Review
7. Proposed Mechanisms of Targeting COVID-19 by Delivering Mesenchymal Stem Cells and Their Exosomes to Damaged Organs.Stem cell reviews and reports · 2021
   Review
8. MSC Based Therapies to Prevent or Treat BPD-A Narrative Review on Advances and Ongoing Challenges.International journal of molecular sciences · 2021
   Review
9. The Potential Role of Extracellular Vesicles in COVID-19 Treatment: Opportunity and Challenge.Frontiers in molecular biosciences · 2021
   Review
10. Targeted Mitochondrial Therapy With Over-Expressed MAVS Protein From Mesenchymal Stem Cells: A New Therapeutic Approach for COVID-19.Frontiers in cell and developmental biology · 2021
    Article
11. The conundrum of using hyperoxia in COVID-19 treatment strategies: may intermittent therapeutic hyperoxia play a helpful role in the expression of the surface receptors ACE2 and Furin in lung tissue via triggering of HIF-1α?Intensive care medicine experimental · 2020
    Article
12. Mesenchymal stromal cells and their secreted extracellular vesicles as therapeutic tools for COVID-19 pneumonia?Journal of controlled release : official journal of the Controlled Release Society · 2020
    Review
13. Present and Future of Bronchopulmonary Dysplasia.Journal of clinical medicine · 2020
    Review
14. Anti-placental growth factor antibody ameliorates hyperoxia-mediated impairment of lung development in neonatal rats.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2020
    Article
15. Current understanding of the role of Adipose-derived Extracellular Vesicles in Metabolic Homeostasis and Diseases: Communication from the distance between cells/tissues.Theranostics · 2020
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors at 2 institutions in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as